

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: January 13, 2006

ATTY DOCKET NO.  
2005\_1392ASERIAL NO.  
10/549,665APPLICANT  
Adrian MERLO et al.FILING DATE  
September 19, 2005

GROUP



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AG	02/24235	3/2002	WO			
	AH	01/02021	1/2001	WO			
	AI	1 283 216	2/2003	EP			
	AJ						
	AK						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	A. Heppeler et al., "Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides", Current Medicinal Chemistry, Vol. 7, No. 9, pp. 971-994, 2000.
	AM	T. K. Nikula et al., "Improved Method for Labelling DOTA-Analogues with <sup>213</sup> Bi, <sup>225</sup> Ac and Lanthanides", Abstracts of Papers 225 ACS National Meeting, March 23, 2003, page Nucl-67 (1), XP008023978, Abstract.
	AN	J. Fichna et al., "Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging", Bioconjugate Chem., Vol. 14, pp. 3-17, 2003.
	AO	M. Laznicek et al., "Octreotide and Octreotate Derivatives Radiolabeled with Yttrium: Pharmacokinetics in Rats", Cancer Biotherapy & Radiopharmaceuticals, Vol. 17, No. 5, pp. 527-533, 2002.

EXAMINER

/Leah Schlientz/

DATE CONSIDERED

03/12/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/